Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Evidence dashboardStudies since 2012Updated Jul 31, 2026
DulaglutideClinical Trials.
A source-linked view of every Dulaglutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 75
- Recruiting
- 8
- Completed
- 41
- Terminated
- 2
- Results posted
- 15
- Average enrollment
- 565
- Countries
- 36
- Highest phase
- Phase 4
Largest indexed study
23,280,000 participants · NCT07188545 →Developer / research origin
Eli Lilly
Evidence summary
Activity is not efficacy.
Dulaglutide appears in 75 indexed studies: 8 recruiting, 41 completed and 15 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Dulaglutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly · Type 2 Diabetes
Phase 3
Recruiting
55
2026-07
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly · Diabetes Mellitus, Type 2
Phase 3
Not yet recruiting
170
2026-07
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
ProGen. Co., Ltd. · Type 2 Diabetes
Phase 2
Not yet recruiting
60
2026-07
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus
Ain Shams University · Menstrual Irregularities · Type1 Diabetes Mellitus
Phase 1 / Phase 2
Enrolling by invitation
50
2026-06
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
University of Pennsylvania · Cystic Fibrosis · Pancreatic Insufficiency
Phase 2
Recruiting
30
2026-05
Showing 6 of 24 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
Brigham and Women's Hospital · Type 2 Diabetes
Not applicable
Completed
300,000
2026-07
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Brigham and Women's Hospital · Type 2 Diabetes · Overweight
Not applicable
Completed
60,000
2026-07
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
Brigham and Women's Hospital · Type 2 Diabetes Mellitus · Obesity
Not applicable
Completed
120,000
2026-07
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly · Type 2 Diabetes Mellitus
Phase 3
Completed
13,299
2026-07
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Brigham and Women's Hospital · Type 2 Diabetes
Not applicable
Completed
70,000
2026-05
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Type 2 Diabetes Mellitus
Phase 3
Completed
632
2026-04
Showing 6 of 41 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
University of Virginia · Diabetes Mellitus, Type 1 · Endothelial Dysfunction
Phase 2
Suspended
47
2026-04
Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients
Emory University · Hyperglycemia Stress
Phase 4
Terminated
16
2025-01
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
Emory University · Stress Hyperglycemia
Phase 4
Terminated
28
2024-05
Full study index
Search Dulaglutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
75 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 39043396 ↗Mahase E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024 Jul 23;386:q1645. doi: 10.1136/bmj.q1645. No abstract available.Linked from NCT07702461PMID 33239350 ↗Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, Carty C, Chaput JP, Chastin S, Chou R, Dempsey PC, DiPietro L, Ekelund U, Firth J, Friedenreich CM, Garcia L, Gichu M, Jago R, Katzmarzyk PT, Lambert E, Leitzmann M, Milton K, Ortega FB, Ranasinghe C, Stamatakis E, Tiedemann A, Troiano RP, van der Ploeg HP, Wari V, Willumsen JF. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020 Dec;54(24):1451-1462. doi: 10.1136/bjsports-2020-102955.Linked from NCT07702461PMID 41843416 ↗Currier BS, D'Souza AC, Singh MAF, Lowisz CV, Rawson ES, Schoenfeld BJ, Smith-Ryan AE, Steen JP, Thomas GA, Triplett NT, Washington TA, Werner TJ, Phillips SM. American College of Sports Medicine Position Stand. Resistance Training Prescription for Muscle Function, Hypertrophy, and Physical Performance in Healthy Adults: An Overview of Reviews. Med Sci Sports Exerc. 2026 Apr 1;58(4):851-872. doi: 10.1249/MSS.0000000000003897. Epub 2026 Mar 5.Linked from NCT07702461PMID 36841762 ↗Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, Rosenkilde M, Bogh AF, Gliemann L, Jensen JB, Antoniades C, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023 Feb 25;22(1):41. doi: 10.1186/s12933-023-01765-z.Linked from NCT07702461PMID 38629387 ↗Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024 Apr;25(5):611-619. doi: 10.1080/14656566.2024.2343092. Epub 2024 Apr 18.Linked from NCT07702461PMID 38937282 ↗Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27.Linked from NCT07702461PMID 35237446 ↗Shakespear-Druery J, De Cocker K, Biddle SJH, Bennie J. Muscle-Strengthening Exercise Questionnaire (MSEQ): an assessment of concurrent validity and test-retest reliability. BMJ Open Sport Exerc Med. 2022 Feb 14;8(1):e001225. doi: 10.1136/bmjsem-2021-001225. eCollection 2022.Linked from NCT07702461PMID 41903177 ↗Nissen SE, Wolski K, D'Alessio D, Weerakkody G, Kiljanski J, Wiese RJ, Pavo I, Cariou B, Nicholls SJ. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiol. 2026 Jun 1;11(6):544-552. doi: 10.1001/jamacardio.2026.0767.Linked from NCT04255433
Related pages
Keep researching Dulaglutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.